Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMEROL vs FENTANYL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Meperidine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia, sedation, and euphoria. It also has additional weak actions at kappa and delta receptors.
Fentanyl is a synthetic opioid that primarily acts as a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system (CNS), leading to G-protein-coupled receptor activation, inhibition of adenylate cyclase, decreased c AMP production, and modulation of ion channels (e.g., increased potassium efflux, decreased calcium influx). This results in hyperpolarization of neurons and reduced neurotransmitter release, producing analgesia, sedation, and euphoria. Fentanyl also has high lipid solubility, allowing rapid CNS penetration and a fast onset of action.
Moderate to severe pain,Preoperative analgesia,Anesthesia adjunct,Obstetrical analgesia
Anesthesia adjunct (induction and maintenance),Analgesia during anesthesia (e.g., for surgery, mechanical ventilation),Management of acute pain (e.g., procedural sedation),Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations),Patient-controlled analgesia (PCA),Epidural or intrathecal analgesia (off-label),Prehospital analgesia for trauma (off-label)
50-150 mg IM, IV, or SC every 3-4 hours as needed for pain; oral 50-150 mg every 3-4 hours.
25-100 mcg IV every 1-2 hours as needed; 50-100 mcg IM every 1-2 hours; transdermal patch: 12.5-100 mcg/h every 72 hours; transmucosal: 200-1600 mcg as single dose.
2.5-4 hours; prolonged in hepatic impairment (7-11 hours) and elderly.
Terminal elimination half-life is 3–12 hours (mean ~7 hours) in adults; prolonged in elderly, hepatic impairment, or with continuous infusion due to context-sensitive half-life.
Primarily hepatic via hydrolysis to meperidinic acid and N-demethylation to normeperidine (active metabolite) by CYP3A4 and CYP2B6.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 75% of dose; GFR <10 m L/min: administer 50% of dose.
GFR 30-50: use with caution, consider dose reduction by 25-50%; GFR <30: avoid or initiate at 50% of usual dose and titrate slowly; anuric patients: significant accumulation, consider alternative.
Risk of respiratory depression; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of medication errors leading to accidental overdose; risk of serotonin syndrome if used with serotonergic drugs; risk of adrenal insufficiency.
Pregnancy Category C. First trimester: No well-controlled studies; potential risk based on animal studies showing increased skeletal malformations at high doses. Second trimester: Risk of fetal dependence and withdrawal if used chronically. Third trimester: Use near term may cause neonatal respiratory depression, withdrawal syndrome (irritability, tremors, poor feeding), and reduced uterine tone leading to prolonged labor.
First trimester: Limited data; no major malformations reported. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome. High doses near term may cause respiratory depression and neonatal abstinence syndrome.
Meperidine (Demerol) is contraindicated in patients with renal impairment due to accumulation of normeperidine, a neurotoxic metabolite that can cause seizures. Avoid use for >48 hours or doses >600 mg/day. It has a shorter duration of action than morphine and is less effective for severe pain. Serotonin syndrome risk is high when combined with other serotonergic drugs. Do not administer IV if patient has taken MAO inhibitor within 14 days (can cause hyperpyrexia, hypotension, death).
Fentanyl is 50-100 times more potent than morphine. Due to high lipophilicity, onset of analgesia is rapid (within 30 seconds IV) but duration is short. Avoid bolus dosing in opioid-naive patients due to risk of chest wall rigidity. Transdermal patches are not indicated for acute pain due to slow onset and prolonged effect. Monitor for respiratory depression, especially in elderly and those with sleep apnea. Tolerance and physical dependence develop with chronic use. Naloxone is the reversal agent.
No interactions on record
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Desloratadine."
"Fentanyl may increase the central nervous system depressant (CNS depressant) activities of Tapentadol."
"The risk or severity of adverse effects can be increased when Fentanyl is combined with Methadyl acetate."
DEMEROL and FENTANYL are distinct pharmacological agents. DEMEROL belongs to the Opioid Analgesic class and is primarily used for Moderate to severe painPreoperative analgesiaAnesthesia adjunctObstetrical analgesia. FENTANYL belongs to the Opioid Agonist class and is primarily used for Anesthesia adjunct (induction and maintenance)Analgesia during anesthesia (e.g., for surgery, mechanical ventilation)Management of acute pain (e.g., procedural sedation)Treatment of breakthrough pain in opioid-tolerant patients (via transmucosal formulations)Patient-controlled analgesia (PCA)Epidural or intrathecal analgesia (off-label)Prehospital analgesia for trauma (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. DEMEROL carries a safety status of Category C, whereas FENTANYL safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Fentanyl undergoes extensive hepatic metabolism primarily via CYP3A4 N-dealkylation to norfentanyl (inactive) and other minor metabolites. Approximately 75% of the dose is excreted as metabolites in urine (primarily norfentanyl) and about 9% in feces. Less than 7% is excreted unchanged in urine. The terminal half-life is 3–12 hours, influenced by factors such as hepatic function and age.
Renal (90% as metabolites and unchanged drug; ~5% unchanged) and biliary/fecal (minor).
Primarily hepatic metabolism to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for ~75% of the dose (10% unchanged), with ~9% excreted in feces.
65-75% bound (primarily to alpha1-acid glycoprotein and albumin)
~80–85% bound primarily to albumin and alpha-1-acid glycoprotein.
2.4-3.7 L/kg; large due to extensive tissue distribution
Vd: 3–8 L/kg (mean ~4 L/kg), indicating extensive tissue distribution and high lipophilicity.
Oral: 50-60% (first-pass metabolism); IM: ~75%
Transdermal: ~92%; Transmucosal (buccal): ~50%; Oral transmucosal lozenge: ~33%; Intranasal: ~50–70%; Oral (swallowed): very low due to first-pass metabolism (~30% but variable).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with extreme caution, reduce dose by 75%.
1-2 mg/kg IM, IV, or SC every 3-4 hours (max 100 mg/dose); oral 1-2 mg/kg every 3-4 hours.
IV: 1-2 mcg/kg every 2-4 hours; transdermal: not recommended in opioid-naïve children <2 years, start at 12.5 mcg/h if >50 kg; transmucosal: 5-15 mcg/kg as single dose.
Lower initial doses (25-50 mg) with extended intervals (every 4-6 hours); monitor for respiratory depression and CNS effects.
Start at 50% of usual adult dose, titrate cautiously by 25% increments; avoid transdermal in opioid-naïve elderly; monitor for respiratory depression and cognitive impairment.
WARNING: RISK OF RESPIRATORY DEPRESSION, ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF MEDICATION ERRORS (especially with transmucosal formulations).
Avoid alcohol consumption; may enhance CNS depression. No significant food interactions known.
Avoid grapefruit and grapefruit juice as they can increase fentanyl levels via CYP3A4 inhibition. No other significant food interactions. Maintain adequate hydration to prevent constipation.
Meperidine excreted into breast milk with M/P ratio approximately 1.0. Breastfeeding not recommended due to risk of neonatal CNS depression and accumulation of active metabolite normeperidine. Avoid use if breastfeeding; if necessary, monitor infant for sedation and poor feeding.
Fentanyl is excreted into breast milk. Milk-to-plasma ratio is approximately 0.4. Avoid use in lactating women who are poor metabolizers or receive high doses due to risk of infant sedation and respiratory depression.
Pharmacokinetics altered in pregnancy: increased volume of distribution and clearance. Dose adjustment not typically recommended for routine pain management, but lower doses may be required in third trimester due to enhanced CNS sensitivity. Use lowest effective dose for shortest duration. Avoid high doses or prolonged use due to neonatal withdrawal risk.
Clearance of fentanyl is increased during pregnancy, particularly in the third trimester. Dose adjustments may be required; consider increasing dose or frequency. Monitor for efficacy and adjust as needed.
Do not drink alcohol while taking this medication.,Avoid driving or operating machinery until you know how the medication affects you.,Do not increase your dose or frequency without consulting your doctor.,Report any symptoms of serotonin syndrome: agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, vomiting, diarrhea.,This medication may cause constipation; increase fluid intake and fiber.,Do not stop suddenly after prolonged use; withdrawal symptoms may occur.,Store at room temperature, away from light and moisture.
Do not drive or operate heavy machinery until you know how fentanyl affects you.,Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Avoid alcohol and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Store fentanyl patches and other formulations safely out of reach of children and pets; used patches should be folded and flushed down toilet.,Do not share this medication with others; it can cause fatal overdose.,Seek emergency medical help if you experience slow/shallow breathing, extreme drowsiness, or difficulty waking up.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.